Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – Equities researchers at Zacks Research decreased their Q1 2024 EPS estimates for shares of Catalyst Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 11th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.29 per share for the quarter, down from their previous estimate of $0.31. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.13 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q4 2024 earnings at $0.34 EPS and FY2024 earnings at $1.27 EPS.
A number of other brokerages have also issued reports on CPRX. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $22.00 to $24.00 in a report on Tuesday, June 20th. StockNews.com downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Cantor Fitzgerald lifted their price target on Catalyst Pharmaceuticals from $22.00 to $25.00 in a report on Friday, March 17th. Finally, Piper Sandler boosted their price target on Catalyst Pharmaceuticals from $21.00 to $24.00 in a research report on Wednesday, June 21st. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.
Catalyst Pharmaceuticals Price Performance
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.30 by ($0.04). Catalyst Pharmaceuticals had a net margin of 38.76% and a return on equity of 34.72%. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $83.04 million.
Insiders Place Their Bets
In related news, CEO Patrick J. Mcenany sold 26,151 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $13.23, for a total value of $345,977.73. Following the transaction, the chief executive officer now directly owns 3,945,436 shares of the company’s stock, valued at approximately $52,198,118.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 14.10% of the company’s stock.
Institutional Investors Weigh In On Catalyst Pharmaceuticals
Large investors have recently modified their holdings of the business. FMR LLC lifted its position in shares of Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 822 shares during the last quarter. Advisory Services Network LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 260.2% during the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 1,301 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $31,000. Covestor Ltd boosted its holdings in shares of Catalyst Pharmaceuticals by 768.0% during the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,316 shares in the last quarter. Finally, Toth Financial Advisory Corp lifted its holdings in Catalyst Pharmaceuticals by 400.0% during the 1st quarter. Toth Financial Advisory Corp now owns 2,500 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,000 shares during the period. 82.78% of the stock is currently owned by institutional investors.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
- Five stocks we like better than Catalyst Pharmaceuticals
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
